Kweichow Moutai Says 2023 Operating Income Rose
By Jiahui Huang
Chinese liquor giant Kweichow Moutai said its 2023 operating income rose from a year earlier, coming in above guidance and indicating strong fourth-quarter sales.
China's most valuable liquor brand said in a post on its official website that operating income last year rose 20.5% to 164.48 billion yuan ($22.97 billion). That handily beat the company's guidance of CNY149.5 billion provided in late December.
Renhuai-based Moutai, which generates the bulk of its sales in the world's second-largest economy, said total profit in 2023 climbed 19% to CNY108.35 billion.
It didn't provide other metrics.
Moutai is scheduled to release a fuller account of its annual earnings in late March or early April. The company typically revises its preliminary figures.
Moutai's Shanghai-listed shares closed 0.5% lower at CNY1,604.91 on Wednesday, taking losses this year to 7.0%.
Signs of sales strength from Moutai could cheer market watchers at a time when they are looking for fresh indications of the state of consumption in China--the country's main economic driver. Barring the pandemic years, China's growth rate in 2023 was one of its slowest in decades.
Write to Jiahui Huang at jiahui.huang@wsj.com
(END) Dow Jones Newswires
January 31, 2024 05:16 ET (10:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk